Form 4: Nuo Therapeutics Director Sheedy Acquires 125,000 Shares at $0.75

Director Charles E. Sheedy reports the acquisition of 125,000 shares of Nuo Therapeutics, Inc. at $0.75 per share.

Summary

• Charles E. Sheedy, a director of Nuo Therapeutics, Inc., filed a Form 4 disclosing changes in beneficial ownership.
• On September 18, 2024, Sheedy acquired 125,000 shares of common stock at a price of $0.75 per share.
• Following the transaction, Sheedy directly owns 11,437,500 shares of common stock.
• Sheedy also indirectly owns 3,365 shares held in separate trusts for the benefit of his children, disclaiming beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: Neutral sentiment. The document is a regulatory filing detailing a transaction. The purchase itself could be seen as slightly positive, but the document is primarily informational.

Positives

• A director's purchase of shares can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's view of the company's prospects.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates